Search Results - "Yin, Philip D."

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial by Pol, Stanislas, Dr Prof, Ghalib, Reem H, Prof, Rustgi, Vinod K, Prof, Martorell, Claudia, Prof, Everson, Greg T, Prof, Tatum, Harvey A, Prof, Hézode, Christophe, Prof, Lim, Joseph K, Prof, Bronowicki, Jean-Pierre, Prof, Abrams, Gary A, Prof, Bräu, Norbert, Prof, Morris, David W, Prof, Thuluvath, Paul J, Prof, Reindollar, Robert W, Prof, Yin, Philip D, MD, Diva, Ulysses, PhD, Hindes, Robert, MD, McPhee, Fiona, PhD, Hernandez, Dennis, PhD, Wind-Rotolo, Megan, PhD, Hughes, Eric A, MD, Schnittman, Steven, MD

“…Summary Background Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and…”
Get full text

Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection by Toyota, Joji, Karino, Yoshiyasu, Suzuki, Fumitaka, Ikeda, Fusao, Ido, Akio, Tanaka, Katsuaki, Takaguchi, Koichi, Naganuma, Atsushi, Tomita, Eiichi, Chayama, Kazuaki, Fujiyama, Shigetoshi, Inada, Yukiko, Yoshiji, Hitoshi, Watanabe, Hideaki, Ishikawa, Hiroki, Hu, Wenhua, McPhee, Fiona, Linaberry, Misti, Yin, Philip D., Swenson, Eugene Scott, Kumada, Hiromitsu

“…Background DCV-TRIO, a fixed-dose combination of daclatasvir (pangenotypic NS5A inhibitor), asunaprevir (NS3/4A protease inhibitor), and beclabuvir…”
Get full text

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 by Wyles, David L, Ruane, Peter J, Sulkowski, Mark S, Dieterich, Douglas, Luetkemeyer, Anne, Morgan, Timothy R, Sherman, Kenneth E, Dretler, Robin, Fishbein, Dawn, Gathe, Joseph C, Henn, Sarah, Hinestrosa, Federico, Huynh, Charles, McDonald, Cheryl, Mills, Anthony, Overton, Edgar Turner, Ramgopal, Moti, Rashbaum, Bruce, Ray, Graham, Scarsella, Anthony, Yozviak, Joseph, McPhee, Fiona, Liu, Zhaohui, Hughes, Eric, Yin, Philip D, Noviello, Stephanie, Ackerman, Peter

“…Among patients coinfected with HIV-1 and HCV, a sustained HCV virologic response was reported in 97% of patients treated with 12 weeks of daclatasvir plus…”
Get full text

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection by Rodriguez-Torres, Maribel, Läwitz, Eric, Yangco, Bienvenido, Jeffers, Lennox, Han, Steven-Huy, Thuluvath, Paul J, Rustgi, Vinod, Harrison, Stephen, Ghalib, Reem, Vierling, John M, Luketic, Velimir, Zamor, Philippe J, Ravendhran, Natarajan, Morgan, Timothy R, Pearlman, Brian, O’Brien, Christopher, Khallafi, Hicham, Pyrsopoulos, Nikolaos, Kong, George, McPhee, Fiona, Yin, Philip D, Hughes, Eric, Treitel, Michelle

“…AbstractBackground. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with…”
Get full text

Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis by Muir, Andrew J, Poordad, Fred, Lalezari, Jacob, Everson, Gregory, Dore, Gregory J, Herring, Robert, Sheikh, Aasim, Kwo, Paul, Hézode, Christophe, Pockros, Paul J, Tran, Albert, Yozviak, Joseph, Reau, Nancy, Ramji, Alnoor, Stuart, Katherine, Thompson, Alexander J, Vierling, John, Freilich, Bradley, Cooper, James, Ghesquiere, Wayne, Yang, Rong, McPhee, Fiona, Hughes, Eric A, Swenson, E. Scott, Yin, Philip D

“…IMPORTANCE: Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and…”
Get full text

NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection by Zhou, Nannan, Hernandez, Dennis, Ueland, Joseph, Yang, Xiaoyan, Yu, Fei, Sims, Karen, Yin, Philip D., McPhee, Fiona

“…Background. Daclatasvir is an NS5A inhibitor approved for treatment of infection due to hepatitis C virus (HCV) genotypes (GTs) 1–4. To support daclatasvir use…”
Get full text

Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection by Poordad, Fred, Sievert, William, Mollison, Lindsay, Bennett, Michael, Tse, Edmund, Bräu, Norbert, Levin, James, Sepe, Thomas, Lee, Samuel S, Angus, Peter, Conway, Brian, Pol, Stanislas, Boyer, Nathalie, Bronowicki, Jean-Pierre, Jacobson, Ira, Muir, Andrew J, Reddy, K. Rajender, Tam, Edward, Ortiz-Lasanta, Grisell, de Lédinghen, Victor, Sulkowski, Mark, Boparai, Navdeep, McPhee, Fiona, Hughes, Eric, Swenson, E. Scott, Yin, Philip D

“…IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus…”
Get full text

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study by Hézode, Christophe, Hirschfield, Gideon M, Ghesquiere, Wayne, Sievert, William, Rodriguez-Torres, Maribel, Shafran, Stephen D, Thuluvath, Paul J, Tatum, Harvey A, Waked, Imam, Esmat, Gamal, Lawitz, Eric J, Rustgi, Vinod K, Pol, Stanislas, Weis, Nina, Pockros, Paul J, Bourlière, Marc, Serfaty, Lawrence, Vierling, John M, Fried, Michael W, Weiland, Ola, Brunetto, Maurizia R, Everson, Gregory T, Zeuzem, Stefan, Kwo, Paul Y, Sulkowski, Mark, Bräu, Norbert, Hernandez, Dennis, McPhee, Fiona, Wind-Rotolo, Megan, Liu, Zhaohui, Noviello, Stephanie, Hughes, Eric A, Yin, Philip D, Schnittman, Steven

“…To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. In…”
Get more information

Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study) by Sulkowski, Mark S., Flamm, Steve, Kayali, Zeid, Lawitz, Eric J., Kwo, Paul, McPhee, Fiona, Torbeyns, Anne, Hughes, Eric A., Swenson, Eugene S., Yin, Philip D., Linaberry, Misti

“…Background & Aims The phase 2, FOURward study (NCT02175966) investigated short‐duration therapy (4/6 weeks) with four direct‐acting antivirals (DAAs) with…”
Get full text

A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin by Wei, Lai, Zhang, Mingxiang, Xu, Min, Chuang, Wan-Long, Lu, Wei, Xie, Wen, Jia, Zhansheng, Gong, Guozhong, Li, Yueqi, Bae, Si Hyun, Yang, Yong-Feng, Xie, Qing, Lin, Shumei, Chen, Xinyue, Niu, Junqi, Jia, Jidong, Garimella, Tushar, Torbeyns, Anne, McPhee, Fiona, Treitel, Michelle, Yin, Philip D., Mo, Ling

“…Background and Aim Daclatasvir plus asunaprevir has demonstrated efficacy and safety in patients with chronic hepatitis C virus genotype 1b infection. This…”
Get full text

Daclatasvir/asunaprevir/beclabuvir, all‐oral, fixed‐dose combination for patients with chronic hepatitis C virus genotype 1 by Kao, Jia‐Horng, Yu, Ming‐Lung, Peng, Cheng‐Yuan, Heo, Jeong, Chu, Chi‐Jen, Chang, Ting‐Tsung, Lee, Youn‐Jae, Hu, Tsung‐Hui, Yoon, Ki Tae, Paik, Seung Woon, Lim, Young Suk, Ahn, Sang Hoon, Isakov, Vasily, McPhee, Fiona, Hu, Wenhua, Scott Swenson, Eugene, Yin, Philip D, Treitel, Michelle

“…Background and Aim This multinational (Taiwan, South Korea, Russia) phase 3 study evaluated the all‐oral, ribavirin‐free, fixed‐dose combination (DCV‐TRIO) of…”
Get full text

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 by Jacobson, Ira, Zeuzem, Stefan, Flisiak, Robert, Knysz, Brygida, Lueth, Stefan, Zarebska-Michaluk, Dorota, Janczewska, Ewa, Ferenci, Peter, Diago, Moises, Zignego, Anna Linda, Safadi, Rifaat, Baruch, Yaacov, Abdurakhmanov, Dzhamal, Shafran, Stephen, Thabut, Dominique, Bruck, Rafael, Gadano, Adrian, Thompson, Alexander James, Kopit, Justin, McPhee, Fiona, Michener, Tracy, Hughes, Eric A, Yin, Philip D, Noviello, Stephanie

“…AIM: To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin(peg IFN/RBV), in treatment-naive hepatitis C virus(HCV)…”
Get full text

Tu1013 On-Treatment HCV RNA As a Predictor of Sustained Virologie Response in HCV Genotype 3 - Infected Patients Treated With Daclatasvir and Sofosbuvir: Analysis of Phase 3 Ally-3 Study by Kowdley, Kris, Nelson, David, Lalezari, Jacob, Box, Terry, Gitlin, Norman, Poleynard, Gary D, Rabinovitz, Mordechai, Ravendhran, Natarajan, Sheikh, Aasim M, Siddique, Asma, Bhore, Rafia, Yin, Philip D, Noviello, Stephanie, Rana, Khurram

Get full text

Involvement of the Second Extracellular Loop and Transmembrane Residues of CCR5 in Inhibitor Binding and HIV-1 Fusion: Insights into the Mechanism of Allosteric Inhibition by Maeda, Kenji, Das, Debananda, Yin, Philip D., Tsuchiya, Kiyoto, Ogata-Aoki, Hiromi, Nakata, Hirotomo, Norman, Rachael B., Hackney, Lauren A., Takaoka, Yoshikazu, Mitsuya, Hiroaki

“…C-C chemokine receptor 5 (CCR5), a member of G-protein-coupled receptors, serves as a coreceptor for human immunodeficiency virus type 1 (HIV-1). In the…”
Get full text

Tu1012 Effect of Baseline Factors on Response to the Fixed-Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and Beclabuvir (BCV), With or Without Ribavirin (RBV), in Patients With HCV Genotype 1 Infection and Cirrhosis by Hezode, Christophe, Herring, Robert W, Pockros, Paul J, Sheikh, Aasim M, Vierling, John M, Lee, Samuel, Thompson, Alex J, Bhore, Rafia, Hughes, Eric A, Swenson, Eugene S, Yin, Philip D

Get full text

1016 All-Oral 12-Week Combination Treatment With Daclatasvir (DCV) and Sofosbuvir (SOF) in Treatment-Experienced Patients Infected With HCV Genotype (GT) 3: A Subanalysis of the Ally-3 Phase 3 Study by Nelson, David, Bernstein, David, Freilich, Bradley, Lawitz, Eric, Hawkins, Trevor, Pockros, Paul J, Thuluvath, Paul J, Younes, Ziad H, Bennett, Michael, Ghalib, Reem, Ruane, Peter J, Tong, Myron J, Bhore, Rafia, Yin, Philip D, Noviello, Stephanie, Rana, Khurram

Get full text

Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: Successful management with intravitreal injections and monitoring with quantitative PCR by Yin, Philip D, Kurup, Shree K, Fischer, Steven H, Rhee, Henry H, Byrnes, Gordon A, Levy-Clarke, Grace A, Buggage, Ronald R, Nussenblatt, Robert B, Mican, JoAnn M, Wright, Mary E

“…Abstract Background Progressive outer retinal necrosis (PORN) is an ocular disease in individuals with AIDS and is associated with substantial morbidity. The…”
Get full text

INVOLVEMENT OF THE SECOND EXTRACELLULAR LOOP AND TRANSMEMBRANE RESIDUES OF CCR5 IN INHIBITOR BINDING AND HIV-1 FUSION: INSIGHTS TO MECHANISM OF ALLOSTERIC INHIBITION by Maeda, Kenji, Das, Debananda, Yin, Philip D., Tsuchiya, Kiyoto, Ogata-Aoki, Hiromi, Nakata, Hirotomo, Norman, Rachael, Hackney, Lauren, Takaoka, Yoshikazu, Mitsuya, Hiroaki

“…The C-C chemokine receptor 5 (CCR5), a member of G-protein-coupled receptors, serves as a co-receptor for human immunodeficiency virus type 1 (HIV-1). In the…”
Get full text

Correlated Template-Switching Events during Minus-Strand DNA Synthesis: a Mechanism for High Negative Interference during Retroviral Recombination by Anderson, J A, Teufel, 2nd, R J, Yin, P D, Hu, W S

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Nonreciprocal Pseudotyping: Murine Leukemia Virus Proteins Cannot Efficiently Package Spleen Necrosis Virus-Based Vector RNA by Certo, J L, Shook, B F, Yin, P D, Snider, J T, Hu, W S

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text